S-217622 improves respiratory and feverish symptoms associated with COVID 19.
S-217622, vaccine from Shionogi, improved respiratory and feverish symptoms associated with COVID 19 as compared to placebo, according to new data released by the company.
Shionogi said that S 217622 showed no statistically significant difference versus placebo in the total score of 12 COVID-19 symptoms in the PIIb portion of its PII/PIII program. However, it demonstrated an improvement in the composite score of five respiratory and feverish symptoms based on post-hoc analyses.
In the randomized, double-blind PIIb study, the drug also demonstrated rapid clearance of the infectious novel coronavirus. On Day 4, following the third dose, the ratio of patients with positive viral titers declined by some 90% versus placebo. The PIIb part enrolled 428 patients with mild to moderate COVID-19 in Japan (419 patients) and South Korea (nine patients), with roughly 85% of them vaccinated. The study mainly covered patients who got infected after the spread of Omicron and was primarily designed to gauge the antiviral effect of the drug and its efficacy in improving clinical symptoms, when given once daily for five days.
Related news and insights
Roche announced that the European Commission (EC) has granted approval of Polivy (polatuzumab vedotin) in combination with MabThera(rituximab) plus cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).
NICE- National Institute for Health and Care Excellence (UK) Guidance:1.1 Romosozumab (Evenity)from UCB + Amgen, is recommended as an option for treating severe osteoporosis in people after menopause who are at high risk of fracture, only if: they have had a major osteoporotic fracture (spine, hip, forearm or humerus fracture) within 24 months (so are at imminent risk of another fracture) and the company provides romosozumab according to the commercial arrangement.